Showing 1061-1070 of 18563 results for "".
Treatment Advances in Generalized Myasthenia Gravis: Addressing the Nuances of its Underlying Immunopathology
https://reachmd.com/programs/cme/treatment-advances-in-generalized-myasthenia-gravis-addressing-the-nuances-of-its-underlying-immunopathology/29263/Targeted therapy inhibiting the neonatal Fc receptor (FcRn) is resulting in improved outcomes for patients living with gMG. Are you up to date?Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-Making
https://reachmd.com/programs/cme/partnering-with-patients-improving-first-line-treatment-selection-in-upper-gi-cancers-through-shared-decision-making/36579/Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-MakingTruths and Myths About Facial Danger Zones When Injecting Soft Tissue Fillers
https://reachmd.com/programs/modern-aesthetics/truths-and-myths-about-facial-danger-zones-when-injecting-soft-tissue-fillers/39264/Despite the current dip in demand for aesthetic treatments with soft tissue fillers, minimally invasive procedures remain popular and are widely accepted as alternatives to facial surgery.Gut Microbiota and Pediatric MS: New Insights Into Potential Disease Drivers
https://reachmd.com/programs/neurofrontiers/gut-microbiota-and-pediatric-ms-new-insights-into-potential-disease-drivers/26487/A new study investigating the relationship between gut microbiota composition and pediatric-onset multiple sclerosis (MS) offers evidence that a depletion of short-chain fatty acid (SCFA) producers may play a role in the disease's pathogenesis. Discover how these findings have the potential to inforTreatment Options for Invasive Fungal Infections: Why They Don't Always Work
https://reachmd.com/programs/cme/treatment-options-for-invasive-fungal-infections-why-they-dont-always-work/14809/Treatment options for invasive fungal infections are limited, but that’s changing. Find out what’s on the horizon and how to best fight the fungus.IBD and Biosimilars: What Healthcare Professionals Need to Know
https://reachmd.com/programs/gi-insights/ibd-and-biosimilars-what-healthcare-professionals-need-to-know/13835/Do you know how the approval of biosimilars will impact the treatment of inflammatory bowel disease? Hear from our experts and stay up to date!Bronchiectasis Update: Diagnostic Innovations and Therapeutic Frontiers
https://reachmd.com/programs/cme/bronchiectasis-update-diagnostic-innovations-and-therapeutic-frontiers/37233/Bronchiectasis is complex, often underdiagnosed, and frequently misunderstood. Explore key contributors to disease progression, including the role of neutrophilic inflammation and neutrophilic serine proteases, and learn to distinguish bronchiectasis from other respiratory conditions and assess patiImaging in the Diagnosis and Management of ADPKD
https://reachmd.com/programs/cme/imaging-in-the-diagnosis-and-management-of-adpkd/13876/This Expert Exchange webcast is designed to help improve clinicians’ understanding of the role radiologic imaging plays in the diagnosis and management of ADPKD. This activity is not available for continuing education credit.Inhibiting Inflammation in Dry Eye Disease
https://reachmd.com/programs/medical-industry-feature/inhibiting-inflammation-in-dry-eye-disease/24203/Insights into a treatment option designed to target dry eye inflammation.Amyloid and Tau in Alzheimer’s Disease: Insights into Disease Progression
https://reachmd.com/programs/medical-industry-feature/amyloid-tau-alzheimers-disease-progression/37874/The prevalence of dementia is projected to almost double every 20 years.1 Alzheimer’s disease (AD) is the most common cause of dementia,2 making early diagnosis and management increasingly important. Based on our current understanding of its pathology, AD is an amyloid driven tauopathy3 with biomark